Vogt-Koyanagi-Harada Disease: Clinical and Demographic Characteristics of Patients in a Specialized Eye Hospital in Turkey

References

• Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39:265–292
   PubMed Web of Science ®Google Scholar
• Read RW, Rao NA, Cunningham ET. Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol. 2000;11:437–442
   PubMedGoogle Scholar
• Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1980:90:69–75
   PubMed Web of Science ®Google Scholar
• Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 1996;80:1002–1008
   PubMed Web of Science ®Google Scholar
• Sugita S, Sagawa K, Mochizuki M, et al. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int Immunol. 1996;8:799–803
   PubMed Web of Science ®Google Scholar
• Rao NA. Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome. Eye (Lond). 1997;11:213–216
   PubMed Web of Science ®Google Scholar
• Yamaki K, Gocho K, Hayakawa K, et al. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000;165:7323–7329
   PubMed Web of Science ®Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647–652
   PubMed Web of Science ®Google Scholar
• Rajendram R, Evans M, Rao NA. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2005;45:115–134
   PubMedGoogle Scholar
• Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131:599–606
   PubMed Web of Science ®Google Scholar
• Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome: clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682–687
   PubMedGoogle Scholar
• Bykhovskaya I, Thorne JE, Kempen JH, et al. Vogt-Koyanagi-Harada disease: clinical outcomes. Am J Ophthalmol. 2005;140:674–678
   PubMed Web of Science ®Google Scholar
• Forster DJ, Rao NA, Hill RA, et al. Incidence and management of glaucoma in Vogt-Koyanagi-Harada syndrome. Ophthalmology. 1993;100:613–618
   PubMed Web of Science ®Google Scholar
• Kuo IC, Rechdouni A, Rao NA, et al. Subretinal fibrosis in patients with Vogt-Koyanagi-Harada disease. Ophthalmology. 2000;107:1721–1728
   PubMed Web of Science ®Google Scholar
• Al-Kharashi AS, Aldibhi H, Al-Fraykh H, et al. Prognostic factors in Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27:201–210
   PubMedGoogle Scholar
• Tugal-Tutkun I, Ozyazgan Y, Akova YA, et al. The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey. Int Ophthalmol. 2007;27:117–123
   PubMedGoogle Scholar
• Murthy SI, Moreker MR, Sangwan VS, et al. The spectrum of Vogt-Koyanagi-Harada disease in South India. Int Ophthalmol. 2007;27:131–136
   PubMedGoogle Scholar
• Riddington L, Hall AJ, Tait B, et al. Vogt-Koyanagi-Harada syndrome in patients of Vietnamese ancestry. Aust N Z J Ophthalmol. 1996;24:147–149
   PubMedGoogle Scholar
• Chee SP, Jap A, Bacsal K. Spectrum of Vogt-Koyanagi-Harada disease in Singapore. Int Ophthalmol. 2007;27:137–142
   PubMedGoogle Scholar
• Tesavibul N, Sansanayuth W. Vogt-Koyanagi-Harada disease in Thai patients. J Med Assoc Thai. 2005;88:26–30
   PubMedGoogle Scholar
• Ozdal P, Yazıcı A, Tufek M, Ozturk F. Epidemiology of uveitis in a referral hospital in Turkey. Turk J Med Sci. In press
   Google Scholar
• Khairallah M, Zaouali S,Messaoud R, et al. The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa. Int Ophthalmol. 2007;27:125–130
   PubMedGoogle Scholar
• Yang P, Zhang Z, Zhou H, et al. Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr Eye Res. 2005;30:943–948
   PubMed Web of Science ®Google Scholar
• Yamaki K, Hara K, Sakuragi S. Application of revised diagnostic criteria for Vogt-Koyanagi-Harada disease in Japanese patients. Jpn J Ophthalmol. 2005;49:143–148
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Chavis PS, Freeman WR. Vogt-Koyanagi-Harada syndrome in children compared to adults. Acta Ophthalmol Scand. 1998;76:723–726
   PubMedGoogle Scholar
• Sugiura S. Some observations on uveitis in Japan, with special reference to Vogt-Koyanagi-Harada and Behcet diseases. Nihon Ganka Gakkai Zasshi. 1976;80:1285–1326
   PubMedGoogle Scholar
• Yang P, Ren Y, Li B, et al. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114:606–614
   PubMed Web of Science ®Google Scholar
• Rao NA, Gupta A, Dustin L, et al. Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. Ophthalmology. 2010;117:591–599
   PubMed Web of Science ®Google Scholar
• Lertsumitkul S, Whitcup SM, Nussenblatt RB, et al. Subretinal fibrosis and choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Graefes Arch Clin Exp Ophthalmol. 1999;237:1039–1045
   PubMed Web of Science ®Google Scholar
• Sukavatcharin S, Tsai JH, Rao NA. Vogt-Koyanagi-Harada disease in Hispanic patients. Int Ophthalmol. 2007;27:143–148
   PubMedGoogle Scholar
• Ohno S, Minakawa R, Matsuda H. Clinical studies of Vogt-Koyanagi-Haradas disease. Jpn J Ophthalmol. 1988;32:334–343
   PubMed Web of Science ®Google Scholar
• Rao NA. Treatment of Vogt-Koyanagi-Harada disease by corticosteroids and immunosuppressive agents. Ocul Immunol Inflamm. 2006;14:71–72
   PubMed Web of Science ®Google Scholar
• Read RW, Yu F, Accorinti M, et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006;142:119–124
   PubMed Web of Science ®Google Scholar
• Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14:87–90
   PubMed Web of Science ®Google Scholar
• Mondkar SV, Biswas J, Ganesh SK. Analysis of 87 cases with Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol. 2000;44:296–301
   PubMed Web of Science ®Google Scholar
• Agarwal M, Ganesh SK, Biswas J. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2006;14:333–339
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Radwan A, Lebanan MO, et al. Comparison of two different combination immunosuppressive therapies in the treatment of Vogt-Koyonagi-Harada syndrome. Ocul Immunol Inflamm. 2013;21:47–52
   PubMed Web of Science ®Google Scholar